(NUS) Nu Skin Enterprises - NYSE
Sector: Consumer Defensive | Industry: Household & Personal Products | Exchange: NYSE (USA) | Market Cap: 264m USD | Total Return: -29.3% in 12m
Avg Turnover: 3.80M
Qual. Beats: 0
Rev. Trend: -99.6%
Qual. Beats: -3
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
Nu Skin Enterprises, Inc. (NUS) is a global beauty and wellness company specializing in anti-aging skincare, nutritional supplements, and personal care devices. The firm operates through a multi-channel distribution strategy, utilizing direct-to-consumer digital platforms, retail locations, and a network of independent sales representatives across major markets in Asia, the Americas, and Europe.
The company operates within the personal care products sector, a market characterized by high consumer loyalty and recurring revenue streams from consumable goods. Nu Skin’s business model integrates proprietary hardware, such as data-enabled wellness devices, with specialized topical treatments to create a closed-loop product ecosystem.
For more detailed financial metrics and valuation trends, consider reviewing the comprehensive data available on ValueRay.
Headquartered in Provo, Utah, the company manages a diverse brand portfolio including ageLOC, Pharmanex, and Nutricentials. Its research and development efforts focus on the intersection of biotechnology and skincare to maintain competitive differentiation in the premium wellness segment.
- Mainland China revenue stability dictates overall corporate growth and investor sentiment
- Direct selling regulatory shifts in key Asian markets impact distributor retention
- Consumer adoption of high-margin beauty device systems drives product mix profitability
- Global macroeconomic volatility and currency fluctuations pressure international sales margins
- Expansion of digital commerce platforms determines acquisition costs for younger demographics
| Net Income: 54.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -1.72 > 1.0 |
| NWC/Revenue: 18.45% < 20% (prev 15.75%; Δ 2.69% < -1%) |
| CFO/TA 0.06 > 3% & CFO 76.0m > Net Income 54.5m |
| Net Debt (131.2m) to EBITDA (129.6m): 1.01 < 3 |
| Current Ratio: 2.03 > 1.5 & < 3 |
| Outstanding Shares: last quarter (49.4m) vs 12m ago -1.80% < -2% |
| Gross Margin: 69.31% > 18% (prev 67.57%; Δ 1.73% > 0.5%) |
| Asset Turnover: 104.1% > 50% (prev 120.7%; Δ -16.56% > 0%) |
| Interest Coverage Ratio: 5.31 > 6 (EBIT TTM 79.2m / Interest Expense TTM 14.9m) |
| A: 0.19 (Total Current Assets 522.9m - Total Current Liabilities 257.0m) / Total Assets 1.38b |
| B: 1.35 (Retained Earnings 1.86b / Total Assets 1.38b) |
| C: 0.06 (EBIT TTM 79.2m / Avg Total Assets 1.38b) |
| D: 1.36 (Book Value of Equity 794.1m / Total Liabilities 582.7m) |
| Altman-Z'' = 7.48 = AAA |
| DSRI: 0.93 (Receivables 45.0m/56.6m, Revenue 1.44b/1.68b) |
| GMI: 0.98 (GM 67.57% / 69.31%) |
| AQI: 1.00 (AQ_t 0.29 / AQ_t-1 0.29) |
| SGI: 0.86 (Revenue 1.44b / 1.68b) |
| TATA: -0.02 (NI 54.5m - CFO 76.0m) / TA 1.38b) |
| Beneish M = -3.21 (Cap -4..+1) = AA |
As of June 15, 2026, the stock is trading at USD 5.47 with a total of 461,927 shares traded.
Over the past week, the price has changed by +1.86%,
over one month by -12.02%,
over three months by -23.37% and
over the past year by -29.25%.
Nu Skin Enterprises has no consensus analysts rating.
| Analysts Target Price | 7.5 | 37.1% |
P/E Trailing = 5.037
P/E Forward = 5.4407
P/S = 0.1833
P/B = 0.3326
P/EG = 0.7782
Revenue TTM = 1.44b USD
EBIT TTM = 79.2m USD
EBITDA TTM = 129.6m USD
Long Term Debt = 203.6m USD (from longTermDebt, last quarter)
Short Term Debt = 20.0m USD (from shortTermDebt, last quarter)
Debt = 331.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 54.0m
Net Debt = 131.2m USD (calculated: Debt 331.6m - CCE 200.4m)
Enterprise Value = 395.3m USD (264.1m + Debt 331.6m - CCE 200.4m)
Interest Coverage Ratio = 5.31 (Ebit TTM 79.2m / Interest Expense TTM 14.9m)
EV/FCF = 9.51x (Enterprise Value 395.3m / FCF TTM 41.6m)
FCF Yield = 10.52% (FCF TTM 41.6m / Enterprise Value 395.3m)
FCF Margin = 2.88% (FCF TTM 41.6m / Revenue TTM 1.44b)
Net Margin = 3.78% (Net Income TTM 54.5m / Revenue TTM 1.44b)
Gross Margin = 69.31% ((Revenue TTM 1.44b - Cost of Revenue TTM 442.4m) / Revenue TTM)
Gross Margin QoQ = 66.89% (prev 70.74%)
Tobins Q-Ratio = 0.29 (Enterprise Value 395.3m / Total Assets 1.38b)
Interest Expense / Debt = 4.50% (Interest Expense 14.9m / Debt 331.6m)
Taxrate = 15.06% (9.67m / 64.2m)
NOPAT = 67.3m (EBIT 79.2m * (1 - 15.06%))
Current Ratio = 2.03 (Total Current Assets 522.9m / Total Current Liabilities 257.0m)
Debt / Equity = 0.42 (Debt 331.6m / totalStockholderEquity, last quarter 794.1m)
Debt / EBITDA = 1.01 (Net Debt 131.2m / EBITDA 129.6m)
Debt / FCF = 3.16 (Net Debt 131.2m / FCF TTM 41.6m)
Total Stockholder Equity = 796.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.94% (Net Income 54.5m / Total Assets 1.38b)
RoE = 6.84% (Net Income TTM 54.5m / Total Stockholder Equity 796.7m)
RoCE = 7.92% (EBIT 79.2m / Capital Employed (Equity 796.7m + L.T.Debt 203.6m))
RoIC = 6.30% (NOPAT 67.3m / Invested Capital 1.07b)
WACC = 6.82% (E(264.1m)/V(595.7m) * Re(10.59%) + D(331.6m)/V(595.7m) * Rd(4.50%) * (1-Tc(0.15)))
Discount Rate = 10.59% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 20.0 | Cagr: -0.05%
[DCF] Terminal Value 73.10% ; FCFF base≈51.3m ; Y1≈45.0m ; Y5≈36.4m
[DCF] Fair Price = 9.32 (EV 583.6m - Net Debt 131.2m = Equity 452.4m / Shares 48.6m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.01 | # QB: 0
Revenue Correlation: -99.55 | Revenue CAGR: -12.13% | SUE: -1.04 | # QB: -3
EPS current Quarter (2026-06-30): EPS=0.20 | Chg30d=-13.04% | Revisions=-20% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.32 | Chg30d=+10.34% | Revisions=+20% | Analysts=1
EPS current Year (2026-12-31): EPS=1.00 | Chg30d=+0.00% | Revisions=-20% | GrowthEPS=-21.3% | GrowthRev=-4.0%
EPS next Year (2027-12-31): EPS=1.32 | Chg30d=+0.76% | Revisions=+20% | GrowthEPS=+32.0% | GrowthRev=+7.3%